Wire · operational-macro
Legend Biotech (LEGN) Following FDA Clearance For LB2501 Has Its Value Story Back In Focus
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
Legend Biotech received FDA clearance for its LB2501 in vivo CAR-T candidate targeting CD19 and CD20 for B-cell malignancies, sparking a positive share price reaction despite a longer-term decline in value. Analysts view the stock as significantly undervalued based on expected growth and expansion of its cell therapy platform.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 15 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
The FDA's clearance has reopened market access for pioneering CAR-T therapies, making it timely for you to reassess portfolio positions or partnerships in cell therapy development given the renewed investor interest.
◆ Coverage
7 sources · first reported 15 Oct 2026 · latest 16 Oct 2026
◆ Topics